Evidence map›Paper›PMID 28238166›Full record

ArticleJournal of endocrinological investigation2017

The effect of parathyroid hormone (1-84) treatment on serum bone morphogenetic protein 4 and vascular endothelial growth factor in postmenopausal women with established osteoporosis.

J Pepe, C Cipriani, F P Cantatore, A Fabbri, E Pola, V Vinicola, O Raimo, F Biamonte, R Pascone, C Ferrara and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. State of the art in osteoporosis risk assessment and treatment.Journal of endocrinological investigation · 2019
    Review
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

J PepeDepartment of Internal Medicine and Medical Disciplines, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy. jessica.pepe@uniroma1.it.
C CiprianiDepartment of Internal Medicine and Medical Disciplines, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
F P CantatoreRheumatology Unit, University of Foggia, Foggia, Italy.
A FabbriCTO Andrea Alesini Hospital, ASL Roma 2, University of Rome 'Tor Vergata', Rome, Italy.
E PolaPoliclinico Gemelli Hospital, Rome, Italy.
V VinicolaRehabilitation Hospital, I.R.C.C.S Santa Lucia Foundation, Rome, Italy.
O RaimoDepartment of Internal Medicine and Medical Disciplines, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
F BiamonteDepartment of Internal Medicine and Medical Disciplines, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
R PasconeDepartment of Pediatrics, "Sapienza" University, Rome, Italy.
C FerraraDepartment of Public Health and Infectious Diseases, Section Health Statistic, "Sapienza" University Rome, Rome, Italy.
S MinisolaDepartment of Internal Medicine and Medical Disciplines, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Sapienza University of Rome · ITPoliclinico Umberto I · ITAgostino Gemelli University Polyclinic · ITASL Roma · ITFondazione Santa Lucia · ITUniversity of Foggia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the effect of 18 months' parathyroid hormone 1-84 (PTH 1-84) treatment on serum levels of bone morphogenetic protein 4 (BMP4) and vascular endothelial growth factor (VEGF), in postmenopausal women with established osteoporosis.

methodsThirty-seven postmenopausal women with osteoporosis (mean age 72.9 ± 8.1 years old) and 23 healthy controls (mean age 68.9 ± 9.9 years old) were enrolled. Patients were treated with daily subcutaneous injections of PTH (1-84) 100 mcg for 18 months, plus calcium 1 gr and vitamin D 800 IU per os daily. Blood samples were taken every 6 months during the study.

resultsAt baseline, there were no differences considering anthropometric parameters, co-morbidities, current medications used between patients and controls. Mean serum VEGF levels were significantly higher in osteoporotic patients compared to controls (436.7 ± 259.7 vs. 260.3 ± 184.3 pg/ml, p = 0.006), while there were no differences in mean serum values of BMP4 (5.3 ± 1.7 vs. 5.7 ± 1.6 pg/ml, p = 0.40). Serum VEGF levels increased by approximately 20% after 12 months of PTH (1-84) treatment compared to baseline (p = 0.03) and by 22% after 18 months (p = 0.01). A significant increase of 10% in mean serum BMP4 levels was observed after 18 months of PTH (1-84) treatment compared to baseline (p = 0.02). In the control group we found no differences after 18 months compared to baseline in BMP4 (5.7 ± 1.6 vs. 6.0 ± 1.5 pg/ml, p = 0.53) and VEGF (260.3 ± 184.3 vs. 257.4 ± 107.1 pg/ml, p = 0.94).

conclusionsPTH (1-84) treatment increased serum levels of VEGF and BMP4 in postmenopausal women with severe osteoporosis.

Indexed as

AgedBone DensityBone Morphogenetic Protein 4Case-Control StudiesFemaleHumansOsteoporosis, PostmenopausalParathyroid HormonePostmenopausePrognosisVascular Endothelial Growth Factor ABMP4 protein, humanBone Morphogenetic Protein 4Parathyroid HormoneVascular Endothelial Growth Factor AVEGFA protein, humanBone morphogenetic protein 4OsteoporosisParathyroid hormone 1–84Vessel endothelial growth factor

Identifiers

PMID28238166
OpenAlexW2589443458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.